05 Sep 2018, Gergana Bencheva, EMIS Editor
Italian Olon to buy manufacturing facility in India
The move is in line with the continuing expansion of Olon’s global footprint. The acquisition will allow the group to boost its growth, add new projects and develop new generic products for the Indian market, its CEO, Paolo Tubertini, said.
The Mahad site is a reputable API manufacturing facility in India, which provides a number of lifesaving medicines to the local healthcare system as well as to patients around the world. The acquisition is due to be completed in early 2019, Pharmabiz.com added.
Sign in and read the full article in emis.com, or find out more about EMIS. Original source: PharmaBiz